[{"orgOrder":0,"company":"Multiomic Health","sponsor":"Hoxton Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Nephrology","graph2":"Discovery","graph3":"Multiomic Health","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","amount2New":0.01,"dosageForm":"","sponsorNew":"Multiomic Health \/ Hoxton Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Multiomic Health \/ Hoxton Ventures"}]

Find Clinical Drug Pipeline Developments & Deals by Multiomic Health

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The net proceeds of the financing round will be used to to discover precision medicines for metabolic syndrome-related conditions and to demonstrate proof-of-concept for MultiOmic’s MOHSAIC® platform in diabetic kidney disease.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          May 03, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Nephrology

                          Highest Development Status : Discovery

                          Sponsor : Hoxton Ventures

                          Deal Size : $8.6 million

                          Deal Type : Financing

                          blank